Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double Dummy, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening All Administered by Inhalation Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.
Brief Summary: The purpose of this study is to compare the efficacy and safety of GW685698X 100mcg once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening via DISKHALER for 28 days in subjects with persistent bronchial asthma.


Options:
A: Arm Label: GW685698X (fluticasone furoate) 100mcg Morning; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Morning | Arm Label: GW685698X (fluticasone furoate) 100mcg Evening; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Evening | Arm Label: GW685698X (fluticasone furoate) 250mcg Evening; Type: EXPERIMENTAL; Interventions: Drug: GW685698X (fluticasone furoate) 250mcg Evening | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GW685698X (fluticasone furoate) 100mcg Morning, Drug: GW685698X (fluticasone furoate) 100mcg Evening, Drug: GW685698X (fluticasone furoate) 250mcg Evening, Drug: Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 100mcg Morning; Assigned to Arm(s): GW685698X (fluticasone furoate) 100mcg Morning, Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 100mcg Evening; Assigned to Arm(s): GW685698X (fluticasone furoate) 100mcg Evening, Placebo | Intervention Type: DRUG; Name: GW685698X (fluticasone furoate) 250mcg Evening; Assigned to Arm(s): GW685698X (fluticasone furoate) 250mcg Evening, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: FF/UMEC/VI (100/31.25/25) mcg closed triple therapy; Type: EXPERIMENTAL; Interventions: Drug: FF/UMEC/VI (100/31.25/25) mcg, Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/UMEC/VI (100/62.5/25) mcg closed triple therapy; Type: EXPERIMENTAL; Interventions: Drug: FF/UMEC/VI (100/62.5/25) mcg, Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/UMEC/VI (200/31.25/25) mcg closed triple therapy; Type: EXPERIMENTAL; Interventions: Drug: FF/UMEC/VI (200/31.25/25) mcg, Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/UMEC/VI (200/62.5/25) mcg closed triple therapy; Type: EXPERIMENTAL; Interventions: Drug: FF/UMEC/VI (200/62.5/25) mcg, Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/VI (100/25) mcg dual combination therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI (100/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Arm Label: FF/VI (200/25) mcg dual combination therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI (100/25) mcg, Drug: FF/VI (200/25) mcg, Drug: Fluticasone/salmeterol (FSC), Drug: Albuterol/salbutamol, Device: ELLIPTA DPI, Device: DISKUS DPI, Device: METERED-DOSE INHALER (MDI) | Intervention Type: DRUG; Name: FF/UMEC/VI (100/31.25/25) mcg; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy | Intervention Type: DRUG; Name: FF/UMEC/VI (100/62.5/25) mcg; Assigned to Arm(s): FF/UMEC/VI (100/62.5/25) mcg closed triple therapy | Intervention Type: DRUG; Name: FF/UMEC/VI (200/31.25/25) mcg; Assigned to Arm(s): FF/UMEC/VI (200/31.25/25) mcg closed triple therapy | Intervention Type: DRUG; Name: FF/UMEC/VI (200/62.5/25) mcg; Assigned to Arm(s): FF/UMEC/VI (200/62.5/25) mcg closed triple therapy | Intervention Type: DRUG; Name: FF/VI (100/25) mcg; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DRUG; Name: FF/VI (200/25) mcg; Assigned to Arm(s): FF/VI (200/25) mcg dual combination therapy | Intervention Type: DRUG; Name: Fluticasone/salmeterol (FSC); Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DRUG; Name: Albuterol/salbutamol; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DEVICE; Name: ELLIPTA DPI; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DEVICE; Name: DISKUS DPI; Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy | Intervention Type: DEVICE; Name: METERED-DOSE INHALER (MDI); Assigned to Arm(s): FF/UMEC/VI (100/31.25/25) mcg closed triple therapy, FF/UMEC/VI (100/62.5/25) mcg closed triple therapy, FF/UMEC/VI (200/31.25/25) mcg closed triple therapy, FF/UMEC/VI (200/62.5/25) mcg closed triple therapy, FF/VI (100/25) mcg dual combination therapy, FF/VI (200/25) mcg dual combination therapy
C: Arm Label: Fp MDPI 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: albuterol/salbutamol HFA | Arm Label: FLOVENT HFA 110 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT HFA, Drug: albuterol/salbutamol HFA | Arm Label: Fp MDPI 200 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: albuterol/salbutamol HFA | Arm Label: FLOVENT HFA 220 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT HFA, Drug: albuterol/salbutamol HFA | Arm Label: FS MDPI 100/12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: albuterol/salbutamol HFA | Arm Label: ADVAIR DISKUS 250/50 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS, Drug: albuterol/salbutamol HFA | Arm Label: FS MDPI 200/12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: albuterol/salbutamol HFA | Arm Label: ADVAIR DISKUS 500/50 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS, Drug: albuterol/salbutamol HFA | Intervention Type: DRUG; Name: Fp MDPI; Assigned to Arm(s): Fp MDPI 100 mcg, Fp MDPI 200 mcg | Intervention Type: DRUG; Name: FS MDPI; Assigned to Arm(s): FS MDPI 100/12.5 mcg, FS MDPI 200/12.5 mcg | Intervention Type: DRUG; Name: FLOVENT HFA; Assigned to Arm(s): FLOVENT HFA 110 mcg, FLOVENT HFA 220 mcg | Intervention Type: DRUG; Name: ADVAIR DISKUS; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg, ADVAIR DISKUS 500/50 mcg | Intervention Type: DRUG; Name: albuterol/salbutamol HFA; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg, ADVAIR DISKUS 500/50 mcg, FLOVENT HFA 110 mcg, FLOVENT HFA 220 mcg, FS MDPI 100/12.5 mcg, FS MDPI 200/12.5 mcg, Fp MDPI 100 mcg, Fp MDPI 200 mcg
D: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder, Drug: Placebo (2) | Arm Label: Fluticasone propionate/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol Inhalation Powder, Drug: Placebo (1) | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol Inhalation Powder; Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (1); Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (2); Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444)

Answer: A